Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas

Modern Pathology

Volumn 28, Issue 8, 2015, Pages 1064-1073

  Lee, Jen Chieh ^a,b   Jeng, Yung Ming ^a,b   Liau, Jau Yu ^a,b   Tsai, Jia Huei ^a,b   Hsu, Hung Han ^a,b   Yang, Ching Yao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALPHA THALASSEMIA MENTAL RETARDATION SYNDROME X LINKED GENE; ARTICLE; DEATH DOMAIN ASSOCIATED PROTEIN 6 GENE; DEDIFFERENTIATED LIPOSARCOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MYXOSARCOMA; OVERALL SURVIVAL; PHENOTYPE; PLEOMORPHIC LIPOSARCOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; TELOMERE HOMEOSTASIS; WELL DIFFERENTIATED LIPOSARCOMA; CELL DEDIFFERENTIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ATRX PROTEIN, HUMAN; DAXX PROTEIN, HUMAN; DNA HELICASE; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL DEDIFFERENTIATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA HELICASES; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LIPOSARCOMA; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TELOMERE HOMEOSTASIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938418620     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.67     Document Type: Article

References (35)

1. Dei Tos AP, Doglioni C, Piccinin S et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000;190:531-536.
2. Italiano A, Bianchini L, Keslair F et al. HMGA2 is the partner of MDM2 in well-differentiated and dediffer-entiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008;122: 2233-2241.
3. Aman P, Ron D, Mandahl N et al. Rearrangement of the transcription factor gene CHOP in myxoid lipo-sarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992;5:278-285.
4. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993;363:640-644.
5. Mertens F, Fletcher CD, Dal Cin P et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosomes Cancer 1998;22:16-25.
6. Rieker RJ, Joos S, Bartsch C et al. Distinct chromosomal imbalances in pleomorphic and in high-grade dediffer-entiated liposarcomas. Int J Cancer 2002;99:68-73.
7. Hostein I, Coindre JM, Derre J et al. Comparative genomic hybridization study of paraffin-embedded dedifferentiated liposarcoma fixed with Holland Bouin's fluid. Diagn Mol Pathol 2003;12:166-173.
8. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013;152:390-393.
9. Horn S, Figl A, Rachakonda PS et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-961.
10. Huang FW, Hodis E, Xu MJ et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-959.
11. Draskovic I, Londono Vallejo A. Telomere recombination and alternative telomere lengthening mechanisms. Front Biosci (Landmark Ed) 2013;18:1-20.
12. Royle NJ, Foxon J, Jeyapalan JN et al. Telomere length maintenance-an ALTernative mechanism. Cytogenet Genome Res 2008;122:281-291.
13. Cesare AJ, Reddel RR. Alternative lengthening of telo-meres: models, mechanisms and implications. Nat Rev Genet 2010;11:319-330.
14. Henson JD, Reddel RR. Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett 2010;584:3800-3811.
15. Heaphy CM, Subhawong AP, Hong SM et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011;179:1608-1615.
16. Henson JD, Hannay JA, McCarthy SW et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217-225.
17. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331: 1199-1203.
18. Heaphy CM, de Wilde RF, Jiao Y et al. Altered telo-meres in tumors with ATRX and DAXX mutations. Science 2011;333:425.
19. Abedalthagafi M, Phillips JJ, Kim GE et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol 2013;26:1425-1432.
20. Lovejoy CA, Li W, Reisenweber S et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012;8: e1002772.
21. Drane P, Ouararhni K, Depaux A et al. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 2010;24:1253-1265.
22. Goldberg AD, Banaszynski LA, Noh KM et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010;140:678-691.
23. Wong LH, McGhie JD, Sim M et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res 2010;20:351-360.
24. Koelsche C, Renner M, Hartmann W et al. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res 2014;33:33.
25. Johnson JE, Varkonyi RJ, Schwalm J et al. Multiple mechanisms of telomere maintenance exist in lipo-sarcomas. Clin Cancer Res 2005;11:5347-5355.
26. Costa A, Daidone MG, Daprai L et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006;66:8918-8924.
27. Venturini L, Erdas R, Costa A et al. ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. J Pathol 2008;214: 410-414.
28. Venturini L, Motta R, Gronchi A et al. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer 2010;10:254.
29. Liau JY, Lee JC, Wu CT et al. Dedifferentiated lipo-sarcoma with homologous lipoblastic differentiation: expanding the spectrum to include low-grade tumours. Histopathology 2013;62:702-710.
30. Evans HL. Atypical lipomatous tumor, its variants, and its combined forms: a study of 61 cases, with a minimum follow-up of 10 years. Am J Surg Pathol 2007;31:1-14.
31. Liau JY, Tsai JH, Jeng YM et al. Leiomyosarcoma With Alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome. Am J Surg Pathol 2015;39: 236-244.
32. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006;48:13-21.
33. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: lipo-sarcoma. Cancer Genet Cytogenet 2004;155:1-24.
34. Montgomery E, Argani P, Hicks JL et al. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004;164:1523-1529.
35. Flynn RL, Cox KE, Jeitany M et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015;347:273-277.